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One in four deaths in the United States is cancer-related, and colorectal cancer (CRC) is
the second leading cause of cancer-associated deaths. Screening strategies are utilized
but have not reduced disease incidence or mortality. In this regard, there is an interest
in cancer preventive strategies focusing on lifestyle intervention, where specific etiologic
factors involved in cancer initiation, promotion, and progression could be targeted. For
example, exposure to dietary carcinogens, such as nitrosamines and polycyclic aromatic
hydrocarbons influences colon carcinogenesis. Furthermore, dietary deficiencies could
alter sensitivity to genetic damage and influence carcinogen metabolism contributing to
CRC. High alcohol consumption increases the risk of mutations including the fact that
acetaldehyde, an ethanol metabolite, is classified as a group 1 carcinogen.Tobacco smoke
exposure is also a risk factor for cancer development; approximately 20% of CRCs are
associated with smoking. Additionally, obese patients have a higher risk of cancer devel-
opment, which is further supported by the fact that physical activity decreases CRC risk
by 55%. Similarly, chronic inflammatory conditions also increase the risk of CRC devel-
opment. Moreover, the circadian clock alters digestion and regulates other biochemical,
physiological, and behavioral processes that could influence CRC. Taken together, colon
carcinogenesis involves a number of etiological factors, and therefore, to create effective
preventive strategies, molecular targets need to be identified and beleaguered prior to dis-
ease progression. With this in mind, the following is a comprehensive review identifying
downstream target proteins of the above lifestyle risk factors, which are modulated during
colon carcinogenesis and could be targeted for CRC prevention by novel agents including
phytochemicals.
Keywords: colorectal cancer, lifestyle modification, prevention, molecular targets, phytochemicals, silibinin, grape
seed extract
INTRODUCTION
It is projected that by 2030 the number of new cancer cases will
increase by 70% worldwide due to demographic changes alone;
the significant rise is attributed to adoption of western lifestyle
habits (Franceschi and Wild, 2013). Globally colorectal cancer
(CRC) is the second most common cancer in women and the
third most common in men; according to the American cancer
society (ACS) in the United States alone, there are estimated to be
approximately 50,830 deaths associated with CRC in 2013. CRC
diagnostic screening strategies are available, however, compliance
is low, and conventional treatments result in severe toxicity and do
not decrease disease incidence (Diaz et al., 2006; Bretthauer, 2010).
With this in mind, prevention strategies need to be developed and
implemented within the community, based on existing knowledge
about risk factors and natural CRC disease progression. There is
extensive research examining the risk factors for CRC; including
high red meat consumption, high fat low fiber diet, alcohol and
tobacco consumption, obesity, lack of physical activity, and sleep
deprivation (Huxley et al., 2009; Wei et al., 2009; Basterfield and
Mathers, 2010; Chan and Giovannucci, 2010; Thompson et al.,
2011). These lifestyle factors are the major cause of disease bur-
den globally, and combined with physician’s tendency to prescribe
medication rather than prescribing a healthy lifestyle, have resulted
in a global health crisis (Yousefi et al., 2012; Franceschi and Wild,
2013). However, advancing knowledge investigating the molecu-
lar basis of carcinogenesis has created a remarkable opportunity to
develop effective prevention strategies through lifestyle modifica-
tion. Identifying molecular targets of lifestyle modification allows
researchers to develop effective non-toxic interventions, further
allowing physicians to design personalized lifestyle prescriptions
based on patient history, resulting in improved patient health and
well-being.
IDENTIFYING MOLECULAR PATHWAYS INVOLVED IN CRC
ETIOLOGY
Colorectal cancer is a complex multi-factorial disease; prior to
diagnosis, there are decades of complex genetic and environmental
interactions that ultimately lead to disease initiation, promotion,
and progression (Nambiar et al., 2010). The cellular environ-
ment plays a large role in the disease, and as early as 1863, it
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was hypothesized that the origin of cancer was at sites of chronic
inflammation (Balkwill and Mantovani, 2001). During the normal
inflammatory response, anti-inflammatory cytokine production
follows the production of pro-inflammatory cytokines, creat-
ing a balanced environment. Chronic inflammation can be the
result of persistent initiating factors in the surrounding environ-
ment, or faulty repair mechanism resulting in unrepaired damage,
ultimately leading to neoplasia (Coussens and Werb, 2002).
During chronic inflammation, imbalances between the pro-
duction of reactive oxygen species (ROS) and the detoxification of
these reactive species results in oxidative stress with in the target
tissue; this stress can result in DNA damage and further reduce
DNA repair (Coussens and Werb, 2002). On the other hand, cells
can inherit changes in phenotype, independent of alterations in
the DNA; termed epigenetics, more specifically chromatin based
events that regulate the DNA template (Dawson and Kouzarides,
2012). Further alterations in gene methylation and acetylation sta-
tus result in altered chromatin regulators and gene expression
(Dawson and Kouzarides, 2012). These epigenetic changes have
been associated with oncogene modification or abnormal expres-
sion patterns that can lead to the induction and maintenance of
various cancers (Dawson and Kouzarides, 2012). At the same time,
the tumor microenvironment can also alter the DNA template
resulting in modified protein translation, function, and transport
(Xu et al., 2005).
Once the cells are transformed, the extent to which inflam-
matory cell populations infiltrate the tissue depends on the bal-
ance of cytokines released from the tumor microenvironment.
Inflammatory cells are able to produce a wide array of cellular
signals including: ROS, proteases [i.e., MMPs (matrix metallopro-
teinase)], soluble cell death ligands [i.e., TNF-α (tumor necrosis
factor alpha)], interleukins (ILs) (i.e., IL-6), and interferons (IFNs)
(Coussens and Werb, 2002). NFκB is a central mediator of the
immune response that further regulates inducible-nitric oxide
synthase (iNOS) which is an enzyme that catalyzes the forma-
tion of nitric oxide (NO), leading to inflammatory and hormone
signaling modulation (Fujimoto et al., 2005). Additionally, signal-
ing lipid mediators, specifically prostaglandins (PGs), are formed
during oxidation of arachidonic acid (AA) via cyclooxygenases
(COX-1 and COX-2) which are involved in numerous processes
including: inflammation, hormone regulation, and cell growth
(Vane et al., 1998). Inflammatory mediators are also involved in
the regulation of various growth factors and hormones, including
VEGF (vascular endothelial growth factor) and IGF-1 (Insulin-like
growth factor-1), which are involved in tumor cell proliferation
and metastasis (Akagi et al., 1998).
The cells’ response to the above stimuli depends on its ability
to adapt and continue on the path of cell survival, allowing cells to
repair DNA damage and continue through the cell cycle, or direct
toward the path of programed cell death (PCD). Hallmarks of
colon carcinogenesis are uncontrolled cellular proliferation and
resistance to cell death; therefore, strategies that focus on these
processes would be of clinical significance. Proliferative signal-
ing pathways often begin with activation of a receptor tyrosine
kinase (RTK) (i.e., EGFR, epidermal growth factor receptor) by
a growth factor and subsequent downstream protein activation
(i.e., MAPK, mitogen-activated protein kinase) that can lead to
activation of multiple pathways involved not only in prolifera-
tion but also cell cycle regulation and cellular metabolism (Fritz
and Fajas, 2010). Proliferation is controlled by the cell cycle and
involves DNA replication and cellular division; this process is
controlled by a cascade of protein phosphorylation events and
a set of protein checkpoints that can arrest the cell at specific
stages of the cycle (Collins et al., 1997). PCD is an intracellu-
lar process that refers to apoptosis, autophagy, and programed
necrosis. The process of apoptosis is highly complex involving
two main pathways, the extrinsic or death receptor pathway (i.e.,
DR4/DR5) and the intrinsic or mitochondrial-derived pathway
(Elmore, 2007). Autophagy is a lysosomal-dependent pathway
involving degradation and recycling of cellular components; con-
trolled via an autophagy-related gene network (Liu et al., 2012b).
Programed necrosis or necroptosis is a result of the initiation of
different receptor-sensor complexes via various stimuli, including
TNF-α and ROS species (Han et al., 2011). Colorectal carcino-
genesis involves initiating events resulting in genomic alteration,
which leads to neoplastic growth, resulting in the alteration of
microenvironment, and further tumor promotion from adenoma
to adenocarcinoma, ultimately resulting in disease progression or
metastasis, via internal and external cellular stimuli. A wide vari-
ety of cellular pathways are involved through out the colorectal
carcinogenesis process, thus, identifying molecular targets that are
altered in response to lifestyle choices is key in understanding how
to effectively prevent CRC.
BIOLOGICAL RESPONSES OF MEAT CONSUMPTION IN
RELATION TO CRC RISK
Humans over a long period of time have adapted to consum-
ing large amounts of lean red meat; for many adults in the US,
red meat is part of a habitual diet with average consumption of
red meat per day being 128 g (Mann, 2000; Daniel et al., 2011).
However, numerous epidemiological studies suggest an associa-
tion between red and processed meat consumption and the risk
of CRC (Chan et al., 2011). Red meat is considered the intake of
mutton, lamb, veal, pork, and beef, and processed meat is defined
as the total intake of cured or preserved meats, sausages, ham, and
bacon (Chan et al., 2011). To develop prevention strategies that
will reduce CRC risk, we need to further understand the role of
these factors in colorectal carcinogenesis.
Consumption of red and processed meats may induce several
biological responses that could be responsible for the increased
risk of CRC development as shown in Table 1 and Figure 1. White
meat is not associated with an increased risk of CRC, so what
dietary factor/s in red meat increases the risk of cancer devel-
opment? One important dietary factor could be heme, an iron
porphyrin pigment of red meat, present 10-fold higher in red meat
compared to white meat (Schwartz and Ellefson, 1985; Ishikawa
et al., 2010). A free ferrous iron is released when heme oxygenase-1
(HO-1) resolves dietary heme in the intestinal mucosa (Ishikawa
et al., 2010). Iron itself has been linked to the increased produc-
tion of ROS, specifically H2O2, which can further induce genetic
mutations, inflammatory mediators, and other cytotoxic effects
(Klaunig and Kamendulis, 2004; Knobel et al., 2007). H2O2 more
specifically induces IL-8, IL-6, IL-1β, and TNF-α cytokine pro-
duction, and can further activate NFκB and AP-1 transcription
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factors promoting a pro-inflammatory signal (Morcillo et al., 1999;
Haddad et al., 2001; Yamamoto et al., 2003).
Another dietary factor that could contribute to CRC risk is
malondialdehyde (MDA), a known mutagen, which is formed
during lipid peroxidation and found at high levels in the plasma
when beef is consumed compared to chicken (Basu and Marnett,
1983; Toden et al., 2010). MDA exposure results in colonic DNA
damage, and studies have shown that there is a dose-dependent
positive association between MDA plasma levels and the extent
of DNA signal-strand breaks (SSB) and double-strand breaks
(DSB) (Toden et al., 2010). Additionally, red meat consumption
leads to the production of N -nitroso compounds (NOC) in the
large bowel leading to the DNA-adduct formation through the
binding of telomere stabilizing proteins (i.e., TRF2) (O’Callaghan
et al., 2012). Moreover, red meat consumption initiates epige-
netic changes in host DNA; genotoxic exposure results in mod-
ification of NuRD histone deacetylase complexes (HDAC) that
control transcriptional repression, including HDAC-2 (Feng and
Zhang, 2003; Hebels et al., 2012). Furthermore, animal-fat oxida-
tion occurs when red meat is consumed, resulting in formation of
oxysterols and aldehydes that can alter hormone signals such as
TGF-β; these external stimuli can result in uncontrolled prolifer-
ation (Biasi et al., 2008). Apart from these changes, genes that are
involved in cancer metastasis are also modified in response to red
meat exposure; specifically, the Notch signaling pathway, which is
abnormally activated in CRC and plays a key role in epithelial-
mesenchymal transition (EMT) (Bolos et al., 2007; Wang et al.,
2010; Hebels et al., 2012).
IDENTIFYING MOLECULAR TARGETS OF ALCOHOL-INDUCED
CRC
Alcohol (ethanol) by virtue of its oral consumption, not only
reaches the gastrointestinal tract but also reaches every cell of the
body, and is a major risk factor for the development as well as
progression of various forms of cancer including CRC (Boffetta
and Hashibe, 2006; Haas et al., 2012). Alcohol is acknowledged
as a carcinogen by the World Health Organization (WHO) and
the International agency for Research on Cancer (IARC), and its
intake is categorized into less than 12 g of alcohol, moderate alco-
hol intake (12–35 g/day), and high alcohol intake (>35 g/day).
One unit of alcohol is one 12 oz beer, 4 oz of wine, or 1.5 oz
of liquor, which is equivalent to approximately 7.9 g of alcohol
(Kontou et al., 2012). During metabolism, alcohol dehydrogenase
(ADH), catalase, and cytochrome P450 subenzyme 2E1 (CYP2E1)
catalyze the oxidation of alcohol to acetaldehyde (AA), a group
I carcinogen (Haas et al., 2012; Mikko, 2012). The mechanisms
involved in alcohol-induced cancer progression are difficult to
resolve due to the limitations involved in determining individual
risks, because in most cases smoking and chronic inflammation are
additional risk factors common in patients that over consume alco-
hol (Haas et al., 2012). Developing effective prevention strategies
requires knowledge of the existing etiologic factors that contribute
to alcohol-induced carcinogenesis.
The numerous molecular pathways that are involved in alco-
hol exposure and CRC etiology that reviewed in Table 1 and
Figure 2. Chronic alcohol consumption results in nutritional
deficiencies, specifically decreases absorption of folic acid and
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FIGURE 1 | Effect of red meat consumption on signaling pathways
involved in colon carcinogenesis. Consumption of red meat has been
shown to induce epigenetic changes in host DNA. These changes occur
specifically through altering the levels of histone deacetylase-2 (HDAC-2). Red
and processed meat further contains iron, heme, and nitrosyl heme, all of
which at high levels may increase the risk of CRC development. Both heme
and nitrosyl heme undergo catalysis resulting in the formation of N -Nitroso
compounds (NOC); these NOCs can either result in DNA damage or
DNA-adduct formation. Red meat consumption specifically leads to mutations
in p53 and KRAS genes, further leading to the initiation and progression of
colon carcinogenesis. Alternatively, heme catalysis can also lead to generation
of lipid peroxidation end products, such as malondialdehyde (MDA),
4-hydroxynonenal (4-HNE), oxysterols, and aldehydes. MDA exposure can
result in DNA-adduct formation, leading to DNA mutations and aberrant
proliferation, further contributing to the initiation of CRC. 4-HNE is cytotoxic
and genotoxic compound, that targets colon cells that carry a wild-type APC
gene; this selective toxicity results in enhancement of colon cells that carry a
mutated APC gene, resulting in CRC promotion and progression. Additionally
lipid peroxidation results in the formation of oxysterols and aldehydes, which
further alter hormone signaling, specifically TGF-β, ultimately resulting in
uncontrolled proliferation that contributes to the promotion and progression
of CRC. Another major component of red meat is iron, ferric iron (Fe3+) binds
to transferrin, resulting in receptor activation and endocytosis. Ferric iron is
further converted to ferrous iron (Fe2+) via divalent metal transporter 1
(DMT1), which then contributes to the cell’s overall iron pool. Iron has been
linked to the production of reactive oxygen species (ROS), specifically H2O2;
these reactive species can then up regulate inflammatory mediators, such as
NFκB, IL-6, IL-8, IL-1β, and TNF-α, leading to the promotion and progression of
CRC. Furthermore IL-1β signaling up regulates NFκB, which then activates
DMT1 iron transporters, resulting in increased levels of ferrous iron within the
cell, representing a feed-back loop in iron regulation. The illustration also
denotes the modulatory role of lifestyle interventions at various levels on
these aberrant signaling pathways. The photographs of lifestyle interventions
were sourced and adapted from http://www.freedigitalphotos.net/.
vitamins B1, B2, and B12; allowing the cells to become vulnerable
to the increase in ROS resulting in oxidative stress, this environ-
mental change results in variety of pathway alterations within
the cell (Testino, 2011). Furthermore, fermented alcoholic bev-
erages, such as beer and wine, contain compounds that con-
tribute to ROS generation; specifically maleic and succinylic acids
that stimulate gastrin-mediated secretion potentially altering the
colon microflora resulting in increased NO production (Haas
et al., 2012). Additionally, Vitamin A synthesis is mediated via the
CYP2E1 enzyme, which also metabolizes alcohol; this substrate
competition induced from chronic alcohol consumption results
in decreased Vitamin A levels (Testino, 2011). Decreased vitamin
A levels result in decreased expression of the AP-1 gene, which is
involved in cell cycle regulation and inflammation (Testino, 2011).
Likewise, alcohol consumption results in increased inflammation,
as demonstrated by increased secretion of inflammatory media-
tors, such TNF-α and IL-6, when CRC cells are exposed to alcohol
(Zhao et al., 2004; Amin et al., 2009). Moreover, as a result of
long-term alcohol consumption, folate levels are decreased, fur-
ther altering the synthesis of S-adenosylmethionine (SAM), a key
methyl donor involved in epigenetic alterations leading to modi-
fication of gene expression (Sauer et al., 2010). Similarly, alcohol
exposure has been shown to alter the histone methylation pattern
of the p16 gene promoter, resulting in decreased p16 protein lev-
els and uncontrolled cell cycle regulation (Sauer et al., 2010). In
addition, accumulation of intracellular ROS leads to the induction
of NADPH oxidase and downstream pathways such as hypoxia-
inducible factor-1α (HIF-1α) signaling; leading to up regulation
of PI3K/AKT and VEGF signaling, which are involved in apoptotic
and metastatic signaling (Morgensztern and McLeod, 2005; Wang
et al., 2012a). Likewise more proliferative and metastatic pathways
are modulated by alcohol consumption; these include MMP-2,
MMP-7, MMP-9, EGFR, and ERK 1/2, which in turn promote
proliferative and EMT transition pathways (Forsyth et al., 2010).
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FIGURE 2 | Effect of chronic alcohol consumption on the growth and
development of colon carcinogenesis. Chronic consumption of alcohol
leads to deficiency of vitamins-A, B1, B2, B12, and folic acid. These
deficiencies can further lead to alterations in epigenetic regulators;
specifically, folate deficiency leads to altered S-adenosylmethionine (SAM)
synthesis, resulting in altered p16 gene expression. These epigenetic
modifications are involved in the initiation and promotion of CRC. Beer
consumption can lead to increased reactive oxygen species (ROS).
Specifically, maleic and succinylic acids that are found in beer can result in
increase gastric secretion; this increase in acidic environment leads to
alteration in the microflora present in the gut, ultimately resulting in increased
ROS production. Consumed ethanol is metabolized via oxidation to
acetaldehyde (AA); this metabolism is mediated via alcohol dehydrogenase
(ADH), cytochrome P450 subenzyme 2E1 (CYP2E1), and catalase. Additional
metabolic byproducts of ethanol metabolism include ROS, which are released
during the CYP2E1 oxidation reaction; these reactive intermediates enhance
lipid peroxidation leading to DNA-adduct formation. Adduct formation can
then result in DNA mutations, specifically in the p53 gene, which contributes
to the initiation and promotion of CRC. AA alone is a mutagenic compound
known to form adducts with DNA and proteins, as well as, induce DNA
mutations; furthermore protein adduct formation has been shown to induce
inflammatory responses via TNF-α and IL-6. These inflammatory mediators
further regulate the expression of matrix metalloproteinase MMP-2, -7, and -9,
which are involved in the promotion and progression of CRC. Additionally AA
can be oxidized by aldehydes dehydrogenase 2 (ALDH2) resulting in acetate
and ROS formation; these ROS species have been indicated in the activation
of NADPH oxidase. NADPH oxidase is an enzyme complex that further
modulates downstream effectors proteins, such as ERK1/2 and HIF-1α
signaling; this down stream protein modification results in alteration of
proliferative and metastatic signaling pathways, which are involved in CRC
promotion and progression. The illustration also denotes the modulatory role
of lifestyle interventions at various levels on these aberrant signaling
pathways. The photographs of lifestyle interventions were sourced and
adapted from http://www.freedigitalphotos.net/.
MOLECULAR MECHANISMS OF TOBACCO-INDUCED
COLORECTAL CARCINOGENESIS
Everyday humans are exposed to a variety of toxic and carcinogenic
compounds due to life style habits including smoking tobacco. It
has been estimated that tobacco has killed more than five mil-
lion people in 2008 and will be responsible for the death of
more than eight million by 2030 (Lodovici and Bigagli, 2009).
A wide variety of malignancies are associated with tobacco con-
sumption, with the strongest associations seen not only in the
respiratory tract, but the gastrointestinal and urogenital systems;
it is estimated that approximately 20% of CRC cases can be attrib-
uted to tobacco exposure (Giovannucci and Martinez, 1996; Tsoi
et al., 2009). The major classes of carcinogenic compounds in
tobacco smoke are polycyclic aromatic hydrocarbons (PAHs), aro-
matic amines, nitrosamines, and heterocyclic amines (HCAs);
these carcinogenic compounds can enter the alimentary tract
or the circulatory systems (Fischer et al., 1990; Kasahara et al.,
2008). With in the body these compounds are then metabo-
lized by CYPs (CYP1A1, CYP1A2, CYP2E1, CYP2A6), leading to
DNA-adduct formation or by glutathione S-transferases (GSTs)
(GSTM1, GSTT1, GSTP1) leading to excretion (Barrowman et al.,
1989; Guengerich and Shimada, 1991; Alexandrov et al., 1996; Koh
et al., 2011). Identifying the molecular mechanisms involved in
tobacco detoxification allows the development of effective lifestyle
modification strategies to prevent CRC development in tobacco
smokers.
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There are multiple molecular pathways involved in tobacco
exposure and CRC etiology that are reviewed in Table 1 and
Figure 3. Nicotine exposure results in the activation of nicotinic
acetylcholine receptors (nAChRs) and may contribute to cancer
progression; coupled with the fact that as tumors progress there
is an increased expression of nAChRs, further demonstrating the
involvement of this pathway during carcinogenesis (Russo et al.,
2012). Nitrosamines, such as nicotine-derived nitrosamine ketone
(NNK), are high affinity ligands for the nAChR signaling and have
been shown to increase intracellular ROS levels in human CRC
cells (Ye et al., 2004). This oxidative stress triggers activation of
inflammatory pathways including that of NFκB, which further
acts as a positive regulator of COX-2 expression (Kosaka et al.,
1994). There are additional biomarkers that indicate tobacco expo-
sure; these biomarkers include oxidative DNA base modification
or DNA-adduct formation, both of which have been shown to
be elevated in colon tissue of smokers (Alexandrov et al., 1996;
Kasahara et al., 2008; Lodovici and Bigagli, 2009). These events
trigger DNA repair, specifically base excision repair (BER) path-
way,which is one of the four major DNA repair pathways, involving
multiple proteins such as OGG1,APEX1/APE1,and XRCC1 (Kasa-
hara et al., 2008). Another potential mechanism involved in the
initiation of tobacco-induced colorectal carcinogenesis could be
epigenetic changes, resulting in KRAS and BRAF gene silencing
FIGURE 3 | Effect of cigarette smoke on the etiology of colon
carcinogenesis. Cigarette smoke contains nicotine as well as numerous
carcinogenic compounds that effect the initiation, promotion, and progression
of colorectal cancer (CRC). These carcinogenic compounds include polycyclic
aromatic hydrocarbons (PAHs), heterocyclic amines (HCAs), and aromatic
amines. These compounds have the ability to induce epigenetic changes in
KRAS and BRAF genes; both these genes are important in preventing the
initiation of CRC. Furthermore, these carcinogenic compounds can be
bioactivated via cytochrome P450 subenzyme (CYPs); this activation can
result in DNA-adduct formation, potentially resulting in DNA mutations in
KRAS, BRAF, and MYC if the DNA damage is not repaired. DNA repair
pathways such as the base excision repair (BER) pathway can reverse the
damage induced by these carcinogens through up regulation of various repair
proteins such as, OGG1, APEX1/APE1, and XRCC1. Alternatively these
carcinogenic compounds can be excreted from the body via glutathione
S-transferases (GSTs) and/or UDP-glucuronosyltransferases (UGTs). Specific
carcinogenic compounds, such as nicotine-derived nitrosamine ketone (NNK)
have been shown to induce the production of ROS; these reactive
intermediates can then activate numerous molecular pathways including
MAPK and NFκB. The MAPK signaling cascade has numerous potential
protein targets, including NFκB, AP-1, and C-myc; the activation of these
pathways can further result in increased inflammatory markers such as
COX-2, leading to the initiation and promotion of CRC. Additionally, NNK can
activate nicotinic acetylcholine receptors (nAChRs), resulting in β-adrenaline
upregulation; β-adrenaline can up regulate COX-2 levels, further leading to
VEGF upregulation. Alternatively β-adrenaline can bind and activate the
β-adrenaline receptor leading to cascade activation; receptor stimulation
triggers ERK1/2 activation leading to up regulation of downstream targets
such as, BCL-2, Bad, and AP-1. The downstream targets of the β-adrenaline
receptor lead to the induction of apoptosis and further activation of metastatic
proteins such as MMPs. Additionally, cigarette smoke contains nicotine which
can activate multiple cell membrane receptors including, nAChRs,
β-adrenaline, and EGFR. Activation of these membrane receptors leads to the
up regulation of inflammatory, apoptotic, and metastatic proteins, such as
COX-2, Bad, BCL-2, AP-1, and VEGF. The illustration also denotes the
modulatory role of lifestyle interventions at various levels on these aberrant
signaling pathways. The photographs of lifestyle interventions were sourced
and adapted from http://www.freedigitalphotos.net/.
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that have been observed in the majority of the diagnosed CRC
cases (Samowitz et al., 2006; Rosenberg et al., 2007).
Another class of receptors involved in nicotine signaling
includes β-adrenoceptors, which can initiate a number of phys-
iological responses, including metabolic and immunomodulatory
responses (Civantos Calzada and Aleixandre de Artinano, 2001;
Oberbeck, 2006). Once activated, these receptors increase inflam-
matory signals and metastatic mediators, such as COX-2 and
MMP-2 (Schuller et al., 1999; Hori et al., 2011). Together with
nAChR signaling, β-adrenoceptors have been linked to metastatic
growth factors, such as VEGF (Lutgendorf et al., 2003; Wong et al.,
2007). Chronic nAChRs and β-adrenoceptors activation due to
tobacco smoke exposure has further been linked to apoptotic sig-
naling; specifically via phosphorylation of pro-apoptotic proteins,
BCL-2 and BAD (Heusch and Maneckjee, 1998; Jin et al., 2004).
In addition, smoke inhalation initiates and promotes prolifera-
tive pathways, specifically MAPK signaling, which is activated in
response to NNK exposure (Ye et al., 2004).
PHYSIOLOGICAL RESPONSES TO PHYSICAL ACTIVITY AND
OBESITY-INDUCED CRC
According to the Center for Disease Control (CDC) and the
WHO, obesity and cancer are two major epidemics in this cen-
tury, and prevalence has dramatically increased in the last few
decades. High consumption of processed foods, animal fat, and
a high calorie diet are risk factors for CRC development. Over-
weight is defined as those who have a body mass index (BMI)
≥25 kg/m2, obese individuals have a BMI ≥30 kg/m2; currently
66% of adults are overweight and 33% are obese (Flegal et al.,
2012; Vucenik and Stains, 2012). In 2008, there were over 500
million people that were in the obese category, as a result of a
chronic positive energy balance. This lack of equilibrium leads
to the systemic secretion of various factors, such as TNF-α, IL-
6, insulin, insulin-like growth factor-1 (IGF-1), adiponectin, and
leptin, which play an important role in carcinogenesis includ-
ing CRC (Harvey et al., 2012; Vucenik and Stains, 2012). Over
the last 20 years, there has been a growing interest in the benefits
of physical activity and cancer etiology; current physical activity
guidelines recommend healthy adults to perform a minimum of
60-min moderate-intensity or 30-min of vigorous-intensity exer-
cise daily to promote health, according to the American Institute
of Cancer Research (AICR) (Wiseman, 2008). There are a num-
ber of observational studies examining prevention strategies with
convincing evidence that physical activity reduces CRC risk, when
comparing the most active with the least active individuals (Winzer
et al., 2011). Repeated aerobic exercise has shown to decrease blood
pressure, fasting glucose, insulin, and atherogenic lipids (Peder-
sen and Fischer, 2007). Currently, there are numerous pathways
that are modified with physical activity that could target colon
carcinogenesis; specifically, hormonal, inflammatory, angiogenic,
apoptotic, and proliferative pathways (Winzer et al., 2011). Identi-
fying biomarkers and further examining their mechanistic role in
CRC initiation, promotion, and progression will, thus, further the
development of physical activity interventions for the prevention
of CRC.
Additionally, Table 1 and Figure 4 is a review of the numer-
ous cellular pathways that are affected by physical activity and
obesity, which are further involved in CRC etiology. During exer-
cise, a 10- to 40-fold increase in oxygen uptake occurs relative
to the resting state which can cause an increased ROS forma-
tion (Na and Oliynyk, 2011). It has been reported that vigorous
exhausting exercise increases DNA damage, while moderate exer-
cise does not increase, but instead, alleviates the oxidative stress
and DNA damage (Poulsen et al., 1999; Sato et al., 2003). Exam-
ining detoxification pathways during physical activity revealed
that superoxide dismutase (SOD) was up regulated, as well as,
downstream protein players, such as nuclear transcription fac-
tor erythroid 2p45 (NF-E2)-related factor (Nrf2) (Asghar et al.,
2007). Nrf2 then translocates to the nucleus to initiate transcrip-
tion of additional detoxifying enzymes, such as GSTs (Asghar et al.,
2007). Physical activity has the ability to increase energy expen-
diture and decrease energy intake through hormone modulation;
acute exercise results in increased levels of certain satiety hor-
mones, specifically polypeptide YY, GLP-1, and PP, all of which
are involved in glycogen secretion, the major energy source in the
body (Martins et al., 2008). Leptin is another example of the ability
of physical activity to modulate hormones-leptin levels decrease
with moderate exercise; this hormone is synthesized by adipocytes
and is important in regulating food intake (Ahima et al., 1996).
Furthermore, leptin is involved in proliferative and apoptotic sig-
naling, specifically activation of MAPK and PI3K/AKT pathways
(Cirillo et al., 2008). Correspondingly, proliferative marker such
as proliferating cell nuclear antigen (PCNA) is down regulated
during moderate physical activity (Demarzo et al., 2008).
The increase of adipose tissue observed in obese individuals
results in systemic low-grade inflammation, via up regulation of
TNF-α; this sustained up regulation can lead to chronic inflamma-
tory conditions that elevate the risk of CRC development (Drevon,
2005). However, with regular exercise, the anti-inflammatory
effects of acute bouts of exercise protect against chronic sys-
temic low-grade inflammation. Physical activity has been shown
to increase inflammatory mediators such as IL-6 (Kim et al., 2009;
Brandt and Pedersen, 2010). It is speculated that this increased
IL-6 production during exercise may work in a endocrine-type
fashion and increase hepatic glucose production or lipolysis in adi-
pose tissue (Pedersen and Febbraio, 2008). It is hypothesized that
induction of the adaptive immunity through moderate exercise
can ultimately prevent chronic inflammatory conditions. Further-
more, physical activity was able to decrease the expression of
iNOS and TNF-α in the plasma and colon mucosa, supporting
an overall anti-inflammatory role of moderate exercise (Na and
Oliynyk, 2011). Physical activity was also shown to significantly
decrease the IGF-1/Insulin-like growth factor-binding protein 3
(IGFBP-3) ratios and aberrant β-catenin signaling (Ju et al., 2008).
An inappropriate stabilization, translocation, and activation of β-
catenin are hallmarks of sporadic and familial CRC. Thus, physical
activity modulation of β-catenin results in downstream modula-
tion of oncogenic target genes such as c-myc and VEGF (Zhang
et al., 2001; Barker and Clevers, 2006; Saif and Chu, 2010). More-
over, peroxisome proliferator-activated receptor-α (PPARα) is a
metabolic regulator that regulates glucose and lipid homeostasis;
physical activity targets PPARα, decreasing it’s expression, further
resulting in decreased levels of VEGF, a key regulator of metastasis
(Wang et al., 2006; Peters et al., 2011).
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FIGURE 4 | Effect of physical activity and obesity on the growth and
development of colon carcinogenesis. Vigorous physical activity had been
shown to induce the production of reactive oxygen species (ROS) leading to
DNA-adduct formation, potentially affecting the initiation of colorectal cancer
(CRC). Alternatively, moderate physical exercise has been shown to induce an
innate immune response through IL-6 receptor activation and downstream
protein up regulation. This adaptive immune response protects the organisms
against chronic inflammatory conditions, which are known to increase the risk
of CRC development. Further, moderate physical activity has been shown to
inhibit the expression of other inflammatory mediators, such as iNOS, which
may play a role in chronic inflammatory conditions. Moderate physical activity
has been also shown to alter specific hormones that are related to appetite
and satiety signals; these hormones include YY, GLP-1, and PP, all of which are
involved in glycogen secretion. Practicing moderate physical activity also
results in the up regulation of superoxide dismutase (SOD); this enzyme
further activates detoxification pathways via up regulation of the Nrf2 proteins
and GSTs enzymes. Additionally, SOD inhibits PPAR-α leading to the reduced
expression of VEGF, which is involved in the promotion and progression of
CRC. Obesity is a result of an energy imbalance that results in aberrant
activation of various receptor proteins involved in inflammation, proliferation,
and hormone regulation. This abnormal activation creates an environment that
is chronically inflamed and can result in the initiation, promotion and
progression of CRC. One of the major inflammatory mediators is TNF-α, which
is activated at the cell membrane, resulting in downstream protein cascade
activation.TNF-α activation can result in induction of NFκB and COX-2 signaling
which initiates an inflammatory response. Additionally, the TNF-α receptor
pathway can trigger activation of the GSK3β enzyme; this enzyme regulates
numerous proteins, including β-catenin and NFκB. β-catenin further regulates
other proteins that are involved CRC development; these proteins include
C-myc, cyclin D, and VEGF, which are involved in oncogene signaling, cell cycle
regulation, and metastatic development. Adiponectin is another factor that is
highly expressed in obese individuals, which has been shown to increase
glucose uptake and fatty acid oxidation; once the adiponectin receptor is
activated it results in PKA kinase upregulation, which further inhibits NFκB in
adipocytes. This inhibition ultimately leads to down regulation of cell adhesion
molecules that are important regulators of CRC promotion and progression.
Insulin signaling is another important pathway that is chronically up regulated
in obese individuals; binding of insulin to its receptor triggers a conformational
change that results in the activation of downstream kinase targets such as,
PI3K. PI3K has the ability to trigger PKB kinase activation, which ultimately
results in increased glycogen secretion and decreased gluconeogenesis;
alternatively PI3K can activate the JAK protein kinase, which plays a role in
immune function and inflammatory responses. Another factor that has been
shown to activate the JAK protein is leptin; this factor is secreted from
adipose tissue and in addition to activating JAK it has also been shown to
activate the MAPK signaling cascade. Furthermore, both JAK and MAPK
signaling pathways are involved in the regulation of proliferative and
metastatic associated molecules, such as PCNA and VEGF; both of which are
important regulators of CRC promotion and progression. The illustration also
denotes the modulatory role of lifestyle interventions at various levels on
these aberrant signaling pathways. The photographs of lifestyle interventions
were sourced and adapted from http://www.freedigitalphotos.net/.
CIRCADIAN RHYTHM ALTERATION AND INCREASED RISK
OF CRC
A convincing body of evidence suggests that there are severe reper-
cussions of circadian disruption resulting in physiological and
patho-physiological consequences. This is not surprising, consid-
ering that in last 2.5 billion years during which life has evolved on
the planet, there has been a predictable rhythm between the rotat-
ing surfaces of the earth and the sun. The cells of the most organ-
isms reveal circadian rhythms known as the circadian clock; 24-h
timekeeping in the central clock of the brain and the peripheral
tissues. This circadian clock modulates transcription-translation
feedback loops that are generated by core circadian clock genes,
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including PER1, 2, and 3, and CLOCK (Ko and Takahashi, 2006).
Suppression of these genes occurs during CRC promotion and
progression; coupled with the fact that Per2 knock out mice are
associated with a tumor prone-phenotype, indicates the important
role this 24-h clock plays during carcinogenesis (Fu et al., 2002;
Sjoblom et al., 2006). Correspondingly, each organism has evolved
mechanisms to adjust to the solar day and deal with cycles of energy
overload during the day and cycles of dearth at night; protecting
essential machinery from excess solar, chemical, and biochemi-
cal energy. In addition, biological timing of DNA damage repair,
cellular proliferation, and apoptosis are under the control of the
circadian rhythm (Hrushesky et al., 1998; Granda et al., 2005; Kang
et al., 2009). Furthermore, considering women and men that are
chronically exposed to night-shift work, have a 50% increased risk
of developing CRC compared to day shift workers; understanding
this circadian time structure and the biological targets provides
unique opportunities to prevent colon carcinogenesis (Hrushesky
et al., 2009). Identifying molecular targets whose expression is con-
trolled by the circadian clock is key when designing prevention
strategies for CRC.
A review of the circadian rhythm pathways that are involved in
CRC etiology is shown in Table 1 and Figure 5. The circadian clock
also controls pathways involved in detoxification enzyme expres-
sion, such as CYPs; furthermore, it has been shown that these
detoxification genes are expressed in a rhythmic pattern through-
out the GI tract (Hoogerwerf et al., 2007; Sladek et al., 2007). Pro-
line and acidic amino acid-rich (PAR) basic leucine zipper (bZip)
transcription factors are also circadian clock-controlled, and form
a complex with hepatic leukemia factor (HLF) or E4 promoter
binding protein-4 (E4BP4); this group of transcription factors are
responsible for xenobiotic detoxification (Murakami et al., 2008).
Moreover, the rhythmic regulation of p21/Wee1 genes controls
numerous physiological processes, which gate other growth and
cell cycle regulators including DNA replication and mitosis (Bjar-
nason et al., 2001; Matsuo et al., 2003). Additionally, elimination
of the Per2 gene in mice resulted in lack of p53 protein activity,
which is involved in DNA repair, cell cycle, and cell death path-
ways (Fu et al., 2002). Cancer cells also express higher levels of
PER2 compared to normal cells; correspondingly, PER2 circadian
expression has been shown to modulate proliferative, cell cycle,
and apoptotic pathways, specifically c-myc, cyclin D, β-catenin,
and VEGF (Zhang et al., 2001; Fu et al., 2002; Wood et al., 2008).
Iron is an important mineral involved in metabolism, respiration
and DNA synthesis; iron is regulated through transferrin recep-
tor 1 (TfR1) which binds and internalizes transferrin and also
exhibits a 24-h rhythm (Sorokin et al., 1989). Furthermore, iron
metabolism and immunity are closely related; TNF-α and IL-6
inflammatory cytokines directly stimulate iron storage proteins
(Brock and Mainou-Fowler, 1986; Torti et al., 1988; Rogers, 1996).
BIOLOGICAL TARGETS OF NUTRACEUTICALS FOR CRC
PREVENTION
A healthy diet is important in maintaining basic physiological
functions within the body. With that in mind, the ACS has rec-
ommended an intake of ≥5 serving of fruits and vegetables and
further limiting the consumption of refined grains, sugars, fats,
and red meat. Fruits and vegetables are part of a large plant
kingdom that is a vast source of phytochemicals; a number of
these compounds have been investigated for their anti-cancer and
chemoprevention efficacy (Ramos, 2008). Furthermore, probiotic
therapy has been shown to exert health benefits and these benefi-
cial organisms further increase the production of various vitamins
such as folic acid. Lifestyle interventions based on natural sources
not only have the potential to prevent carcinogenesis, but also
are beneficial in maintaining good health because they are nat-
ural sources of vitamins, minerals, and fiber. Furthermore, these
nutraceuticals make ideal chemopreventive agents due to their
multi-targeted effects and selective toxicity toward cancer cells.
These nutraceuticals are also efficacious against various forms
of cancer, can be administered by oral route, are accepted by
the general public, and are produced at a low cost (Galati and
O’Brien, 2004). Furthermore, nutraceutical administration can
target numerous cellular processes, all of which are important
regulators during the development of CRC as outlined in Figure 6.
PROBIOTIC CONSUMPTION
Residing in the GI tract are a variety of microorganisms com-
prising of bacteria, archaea, viruses, and unicellular eukaryotes,
which are know to augment a variety of immunological and
metabolic pathways (Licciardi et al., 2010; Vipperla and O’Keefe,
2012). Collectively, there are over 800 species and 7000 strains
that form over 100-trillion super colonies, which are influenced
by several factors including diet, environment, stress, and dis-
ease (Burk et al., 2003; Vipperla and O’Keefe, 2012). Intestinal
microbial composition has become an emerging factor in CRC
susceptibility, since these organisms impact multiple physiological
functions that are related to cancer progression, cell proliferation,
differentiation, metabolism of essential nutrients, and stimula-
tion of intestinal immunity; similarly, probiotics have been shown
to prevent carcinogenesis through a variety of mechanisms (Zhu
et al., 2011; Kumar et al., 2013). The fields of nutrition, micro-
biology, and genomics are converging rapidly, providing insight
into the molecular mechanisms involved in the chemopreven-
tive efficacy of probiotics; further fostering the development of
inexpensive preventive therapies for CRC. The development of
probiotic-based CRC prevention therapy has great therapeutic
implications, due to its ability to target multiple pathways. Pro-
biotic multi-targeted approach results in increased DNA repair
and detoxification enzymes; furthermore, probiotic consumption
inhibits multiple processes including DNA mutation,DNA-adduct
formation, growth signaling, insulin signaling, and inflammation
as shown in Figures 1–6.
Saccharomyces boulardii is a non-pathogenic yeast species that
has demonstrated antioxidant, metabolic, anti-toxin, and anti-
inflammatory effects (Czerucka et al., 1994; Castagliuolo et al.,
1996; Dalmasso et al., 2006). Compounds produced by the intesti-
nal microbiota, specifically polyamines, have been shown to reduce
oxidative stress (Noack et al., 1998; Rhee et al., 2007). Several
mechanisms by which probiotics may suppress CRC develop-
ment have been suggested, including induction of the adaptive
immune response through increased production of inflamma-
tory cytokines, such as TNF-α and IL-6; further modulating
downstream detoxification pathways (CYPs, GSTs, COX-2) and
reducing the uptake of carcinogenic compounds (Rafter, 2004).
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FIGURE 5 | Effect of circadian rhythm on growth and development of
colon carcinogenesis. The mammalian circadian clock takes 24 h to complete
and is a self-sustaining feedback loop of core clock genes. This group of clock
genes regulate various cellular processes including: detoxification; DNA
repair; proliferation; cell cycle regulation; apoptosis; metastatic signaling, and
inflammation. Furthermore, these cellular processes are then regulated in a
time specific manner; disruption of this circadian rhythm results in
abnormalities in these processes, which contribute to colorectal cancer (CRC)
development. The major genes regulating this 24 h timekeeping are PER1 and
PER2; these genes modulate proliferative, apoptotic, inflammatory, and
metastatic signaling. These genes have been shown to alter the expression of
β-catenin; this protein is involved in proliferation and cell cycle regulation.
Additionally, β-catenin can modulate oncogenic proteins such as C-myc, which
have been shown to regulate iron metabolism; iron metabolism results in
ROS formation, further triggering an inflammatory response and NFκB
activation. Moreover, β-catenin can modify growth and metastatic signals,
mediated via VEGF protein upregulation. Another protein that is under the
control of PER1/PER2 genes is ATM, which is up regulated in response to
cellular stress; this stress regulator protein can further modify downstream
targets, such as p53. The p53 protein, known as the guardian of the genome,
can up regulate p21 protein levels resulting in cell cycle arrest; the arrest
allows the cell to repair the DNA damage that has occurred due to cellular
stress. The PER1/PER2 gene complex further inhibits apoptotic signaling;
specifically through Bim protein inhibition, which results in down regulation of
cleaved-caspase-3 (cc3) and PARP. Alternatively, a group of binding proteins
which are regulated in a circadian manner, including the proteins HLF and
E4BP4 can further modulate detoxification of enzymes, such as cytochrome
P450 subenzyme (CYPs). In addition HLF/E4BP4 binding proteins inhibit the
apoptotic process through inhibition of the pro-apoptotic protein BCL-xL;
BCL-xL inhibition results in down regulation of cleaved-caspase-9 (cc9).
Additional genetic regulators of the circadian process are p21 andWEE1;
these genes are involved in numerous cellular processes including
proliferation, cell cycle regulation, and oncogene signaling. BothWEE1 and
p21 regulate Cyclin D and Cyclin E expression; these cyclin proteins are
involved in cell cycle regulation, which is abnormally regulated during CRC
development. Additionally, p21 genetic regulation can lead to the induction of
cellular apoptotic signals via cc3 induction; p21 can further regulate oncogenic
proteins such as C-myc, which is an important protein in the development and
progression of CRC. The illustration also denotes the modulatory role of
lifestyle interventions at various levels on these aberrant signaling pathways.
The photographs of lifestyle interventions were sourced and adapted from
http://www.freedigitalphotos.net/.
Mechanistic studies indicate that S. boulardii modulates the host-
pathogen interaction; specifically through ERK1/2 MAPK path-
way, which is down regulated in both in vitro and in vivo studies
(Dahan et al., 2003; Chen et al., 2006b). Modulation of the MAPK
pathway can lead to altered hormone, inflammatory, apoptotic,
proliferative, and metastatic signals. Bifidobacterium animalis also
increases polyamine concentrations and has been shown to alter
IGF-1 expression (Matsumoto et al., 2011). Similarly, Bacillus
polyfermenticus, also known to possess chemopreventive efficacy,
has been shown to modulate inflammatory and proliferative sig-
nals, such as those associated with EGFR pathway (Kim et al., 2006;
Lee et al., 2007; Park et al., 2007). The ErbB receptor family, includ-
ing EGFR, is important in cancer development and these family
members are over expressed in various cancers including CRC
(Holbro et al., 2003; Kamath and Buolamwini, 2006). ErbBs also
regulate the cell cycle effecting cyclin D1 levels and further down-
stream oncogenic targets, such as c-myc (Slansky and Farnham,
1996; Rafter, 2004).
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FIGURE 6 | Major molecular targets of dietary agents involved in their
efficacy against colon carcinogenesis. Multiple signaling pathways,
which are modified due to dietary intervention using probiotics, fiber, folic
acid, grape seed extract (GSE), silibinin (Sb), curcumin (CUR), and
Epigallocatechin-3-gallate (EGCG) are listed. The specific pathways
involved are those related to, detoxification, oxidative stress, DNA repair,
oncogenesis, epigenetic silencing, inflammation, hormone signaling,
proliferation, apoptosis, cell cycle, and metastasis. The photographs of
dietary agents were sourced and adapted from http://www.freedigital
photos.net/.
DIETARY FIBER CONSUMPTION
Epidemiological studies indicate that diets rich in fruits, vegeta-
bles, and legumes are of great importance when considering CRC
prevention strategies; these foodstuffs are rich in soluble dietary
fiber (DF) and insoluble fibers, starches, oligosaccharides, and phe-
nolic compounds (Michels, 2005; Vergara-Castaneda et al., 2010).
These DFs are fermented via microorganisms in the colon result-
ing in several physiological effects: production of short chained
fatty acids (SCFA), butyrate, propionate, and acetate; further-
more, these compounds have been shown to induce apoptosis
in human CRC cells (Chen et al., 2006a; Campos-Vega et al.,
2009). Potential mechanisms associated with fiber consumption
and reduced CRC risk include: dilution of carcinogens, reduction
of transit time, production of SCFAs, and reduction of tumor-
promoting substances. Further identifying these molecular mech-
anisms, induced after fiber consumption, plays an important role
in CRC prevention.
Dietary fiber was shown to decrease levels of deoxycholic
acid (DCA), which is a bile acid produced via the dehydroxyla-
tion of primary bile acids and is known to be a direct as well
as indirect tumor promoter in the colon (Zampa et al., 2004;
Stein et al., 2012). Similarly, butyrate induces GSTs in human
CRC cells, which results in carcinogen detoxification (Pool-Zobel
et al., 2005). Furthermore, DF acts as an anti-inflammatory agent
decreasing the levels of IL-6 and TNF-α; additional studies have
also shown the ability of DF to inhibit COX-2 and iNOS gene
expression (Reddy et al., 2000; Kaczmarczyk et al., 2012). Addi-
tionally, DF intake was associated with the increased expression of
DNA repair genes, specifically Apex, Xrcc4, and Xrcc5, which bind
to DNA ligase initiating the repair of DSB (Vergara-Castaneda
et al., 2010). Similarly, butyrate induces apoptotic signaling in
CRC cells through up regulation of BAK, cleaved caspase-3 and
cleaved PARP, and loss of mitochondrial function (Ruemmele
et al., 1999). Furthermore, other SCFA found in legumes altered
the expression of β-catenin, p53, p21, Bax, and casp3 genes in a
carcinogen induced CRC model; all of which are important mod-
ulators of cell cycle, proliferation, and cell death (Feregrino-Perez
et al., 2008). Butyrate also alters epigenetic pathways through
HDAC inhibition in CRC cells (Waldecker et al., 2008). This alter-
ation leads to hyperacetylation of histone residues altering gene
transcription and expression; for example HDAC inhibition via
SCFAs results in upregulation of p21, which is involved in cell
cycle, proliferation, differentiation, and apoptosis (Chen et al.,
2004).
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FOLIC ACID SUPPLEMENTATION
Folates are water-soluble B vitamins that are important cofactors
in DNA synthesis and methylation pathways. Humans need to con-
sume folic acid from exogenous sources to support these essential
functions; good sources of folates include leafy greens, vegetables,
yeast extracts, and citrus fruits (Lucock, 2000). Studies indicate
a 40–60% reduction in the risk of CRC in individuals with high
folate intake (Kim, 1999, 2007). One of the potential mechanisms
in CRC development and progression is folate deficiency (FD);
low levels lead to DNA strand breaks, impaired DNA methyla-
tion, and repair (Kennedy et al., 2011). CRC patients frequently
have decreased folate levels; this deficiency is recognized as one
of the metabolic stressors of colorectal carcinogenesis (Martinez
et al., 2004). The mechanisms and protein targets by which folate
conveys protection against CRC development need to be investi-
gated to develop strategies that effectively target and prevent colon
carcinogenesis. Furthermore, supplementation with folic acid has
clinical potential; this is due to its ability to target multiple path-
ways that are involved in CRC initiation, promotion, and progres-
sion. Folic acid supplementation results in increased DNA repair
proteins, as well as, inhibits multiple processes including DNA
mutation, epigenetic silencing, DNA-adduct formation, growth
signaling, metastatic signaling, and inflammatory processes as
shown in Figures 2–4 and 6.
Folate deficiency may play a role in chronic inflammation
through activation of NF-κB and TNF-α, perpetually creating
inflammatory signals (Wang et al., 2012b). Furthermore, it has
been reported that DNA repair genes are up regulated in folate-
depleted cells, specifically Xrcc5, Apex, and PCNA, supporting folic
acids’ role in DNA repair and synthesis (Duthie et al., 2008; Sadik
and Shaker, 2012). Additionally, PCNA plays a role in prolifera-
tive pathways, as well as, in DNA repair, indicating an additional
mechanism of action in which folic acid is protective against CRC
development. Folate supplementation studies reveal its ability to
increase the stability of p53, which is involved in DNA repair,
proliferation, and cell death pathways (Sadik and Shaker, 2012).
Studies have also elucidated FD role in epigenetic modifications;
its deficiency was associated with decreased global DNA methyla-
tion. Furthermore, different folate species are used for methylation
versus DNA synthesis; these species are distributed differentially in
normal colon tissue compare to cancer tissues (Liu et al., 2012a).
In addition, FD has been shown to enhance EMT signaling in
HCT116 colon cancer cells, through activation of MMPs, up reg-
ulation of Snail, and suppression of E-cadherin (Wang et al.,
2012b).
NUTRITIONAL SUPPLEMENTATION WITH GRAPE SEED EXTRACT
Another supplement that has shown promising chemopreventive
and anti-cancer potential in numerous types of cancer, including
skin, prostate, breast, lung, and CRC, is grape seed extract (GSE)
(Kaur et al., 2009a). GSE supplementation has vast chemopreven-
tive potential; this is due to its ability to target multiple proteins
that are involved in the development of CRC. GSE supplementa-
tion results in increased cancer cell apoptosis, as well as, it inhibits
multiple processes such as signaling related to epigenetics, growth,
proliferation, oncogenes, insulin, metastasis, and inflammation as
shown in Figures 1–6.
Grape seed extract is a complex mixture of polyphenols, specif-
ically proanthocyanidins. In vivo studies with GSE have shown its
anti-inflammatory effects reducing the expression of iNOS and
COX-2 (Velmurugan et al., 2010b). Additionally, GSE has also been
shown to decrease global methylation, and it also decreases DNA-
methytransferase (DNMT) activity and protein levels, indicating
GSE’ role during epigenetic gene modification (Vaid et al., 2012).
Furthermore, GSE inhibited aberrant β-catenin expression and
downstream proteins, cyclin D1, and c-myc (Velmurugan et al.,
2010b). Moreover, mechanistic studies of GSE, at various stages
of CRC development, identified apoptosis induction as the major
factor in the chemopreventive efficacy of GSE against CRC; specif-
ically it induces caspase-3, -8, -9 resulting in the cleavage of PARP,
DNA fragmentation, and PCD (Derry et al., 2012). The apoptotic
effect was specific to CRC cells, with minimal effect on normal
colon epithelial cells; furthermore, this effect was attenuated with
antioxidant treatment, indicating ROS as a potential upstream
stimulus in GSE-induced CRC cell death (Derry et al., 2012). In
addition, GSE has been shown to modulate p21 levels; resulting
in decreased proliferation, leading to cell cycle arrest, and further
downstream pathway activation, including that of ERK1/2 (Kaur
et al., 2006, 2011).
HERBAL SUPPLEMENTATION WITH SILIBININ
Silibinin is a flavonolignan constituent of silymarin, which is
extracted from the milk thistle plant (Silybum marianum). It is
non-toxic and has been used traditionally as well as clinically to
treat various liver diseases and liver complications (Post-White
et al., 2007; Ramasamy and Agarwal, 2008). In past two-decades,
however, silibinin has been investigated for its cancer chemopre-
ventive properties; this natural non-toxic agent is found efficacious
in in vivo preclinical studies against skin, lung, prostate, blad-
der, and CRC cancer models (Rajamanickam and Agarwal, 2008;
Ramasamy and Agarwal, 2008). Several in vitro and in vivo stud-
ies have shown strong preventive and/or therapeutic efficacy of
silibinin against CRC growth and progression (Agarwal et al.,
2003; Rajamanickam and Agarwal, 2008; Velmurugan et al., 2008,
2010a; Kaur et al., 2009b, 2010; Rajamanickam et al., 2009, 2010;
Ravichandran et al., 2010; Raina et al., 2013a,b). Silibinin herbal
supplementation already has potential against CRC; this is due
to its ability to target multiple proteins that are involved in the
initiation, promotion, and progression of CRC. Silibinin supple-
mentation results in increased levels of detoxification enzymes;
it also inhibits multiple processes in carcinogenesis, such as
those involved in DNA mutation, growth/proliferation, metastatic
signaling, and inflammation, as shown in Figures 1–6.
Mechanistic investigations have revealed that the anti-CRC
effects of silibinin were mainly due to its anti-proliferative and pro-
apoptotic effects; further, silibinin strongly inhibits the Wnt/β-
catenin pathway, which is known to play an essential role in the
development and progression of CRC (Rajamanickam and Agar-
wal, 2008; Kaur et al., 2009b, 2010; Rajamanickam et al., 2009).
Toward this effect, silibinin strongly inhibited β-catenin depen-
dent transcriptional activity of Tcf-4 in CRC cells, which was
followed with a decrease in the expression of its transcriptional tar-
gets namely, cyclin D1 and c-myc (Kaur et al., 2010). Furthermore,
the pro-apoptotic effects of silibinin are via the down regulation
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of the anti-apoptotic proteins BCL-2, MCL-1, XIAP, and survivin
and up regulation of pro-apoptotic proteins such as Bax (Velmu-
rugan et al., 2010a; Kauntz et al., 2012a). Additional studies have
shown that silibinin up regulates death receptors, DR4/DR5, at the
transcriptionally level; these receptors are involved in the extrinsic
apoptotic pathway, which further supports the ability of silibinin
to induced apoptotic death as an additional mechanism involved in
its chemopreventive efficacy (Kauntz et al., 2012b). Studies have
also revealed that silibinin strongly inhibits PI-3K-AKT–mTOR
but activates MEK1/2-ERK1/2 pathways for its biological effects
manifested in terms of induction of autophagic type PCD in CRC
cells (Raina et al., 2013a). Silibinin is also known to cause endo-
plasmic reticulum stress in CRC cells together with glucose uptake
inhibition as well as energy restriction, due to interference in essen-
tial cellular processes such as mitochondrial metabolism, phos-
pholipid and protein synthesis; the cellular damage to CRC cells
by silibinin is severe and irreparable (Raina et al., 2013a). Impor-
tantly, it is non-toxic to normal colon cells (Rajamanickam et al.,
2009, 2010). Raina et al. (2013b) have also shown that silibinin has
the potential to strongly inhibit TNFα-induced NF-κB activation
in human CRC cells. These observations were also corroborated by
in vivo studies which showed that anti-inflammatory mechanisms
of silibinin are associated with decreased expression of COX-2 and
iNOS levels, together with inhibition of NF-κB transcriptional
activity (Rajamanickam et al., 2009, 2010; Ravichandran et al.,
2010; Raina et al., 2013b) Moreover, other studies have shown that
silibinin reduced inflammatory mediators such as, TNF-α and IL-
1β; further modifying downstream target proteins, such as MMP-7
(Kauntz et al., 2012a). Likewise, silibinin alters numerous pathways
that are involved in cell invasion and metastasis via alteration of the
JNK pathway and down regulation of AP-1, resulting in decreased
MMP-2 levels (Lin et al., 2012). Silibinin has been shown to alter
xenobiotic metabolizing enzymes; specifically, reducing CYP2E1
activity which is involved in metabolic activation of carcinogens,
and in contrast, silibinin upregulated Phase II enzymes including,
GSTs, which are important in metabolic detoxification (Sangeetha
et al., 2012). Importantly, Hoh et al. (2006) in a completed pilot
study with silibinin in CRC patients with colon adenocarcinoma
have shown high bioavailability of silibinin in colonic tissue of
CRC patients. Thus, the ongoing research on the usefulness of sili-
binin has strong translational implications in the prevention and
management of CRC.
CURCUMIN DIETARY SUPPLEMENTATION
Curcumin (CUR) is the active phenolic compound extracted from
the spice turmeric, derived from the rhizome Curcuma longa.
CUR has been shown to possess anti-cancer and chemopreven-
tive efficacy, and in clinical trials, CUR is effective in reducing
CRC burden (Hatcher et al., 2008). CUR dietary supplementa-
tion has the potential to target multiple signaling pathways that
are involved in the development of CRC. CUR consumption
results in increased cancer cell apoptosis, and levels of detoxifi-
cation enzymes; it also inhibits multiple processes including that
of DNA mutation and signaling related to growth, metastasis, and
inflammation, as shown in Figures 1–6.
Numerous studies have examined pharmacological effects of
CUR in CRC such as induction of apoptosis, and inhibition of
proliferation, oxidative stress and angiogenesis (Shehzad et al.,
2010). CUR has been shown to up regulate GST enzymes in
multiple studies; furthermore, CUR has been shown to induce
ROS in cancer cells, resulting in p21 up regulation and G2/M
cell cycle arrest (Ye et al., 2007; Odenthal et al., 2012; Yogo-
sawa et al., 2012). CUR has also been shown to alter MAPK
pathway resulting in decreased expression of TNF-α and COX-
2 expression in colon mucosa, resulting in an overall decrease
in inflammation (Camacho-Barquero et al., 2007). Additionally,
CUR has been shown to down regulate NF-κB and IL-6 secre-
tion, which are also key regulators of the chronic inflammatory
response (Tu et al., 2012). Concentrated analogs of CUR have
been also shown to inhibit NF-κB translocation, thus result-
ing in a down regulation of gene targets, such as c-myc, cyclin
D1, and BCL-2 (Chen et al., 2011). CUR also induces mito-
chondrial stress and apoptotic cell death through up regulation
of Bax, Bim, Bak, Puma, and Noxa, and down regulation of
anti-apoptotic proteins such as BCL-2 and BCL-xl (Basile et al.,
2013). This induced mitochondrial dysfunction may be due to
the ability of CUR to induce ER-stress resulting in accumula-
tion of ubiquitinated proteins; this protein accumulation could
also induce autophagy (Basile et al., 2013). Furthermore, CUR
analogs were able to decrease VEGF and MMP-9 expression, indi-
cating the ability of CUR to prevent metastatic disease (Chen et al.,
2011).
DIETARY INTERVENTION WITH EGCG
Tea is a one of the worlds most consumed beverages made from
the leaves of Camellia sinensis; Epigallocatechin-3-gallate (EGCG)
is the major polyphenol. Tea has been cultivated and used medi-
cinally for thousands of years due to the beneficial health effects.
Furthermore, it has been extensively studied for its chemopreven-
tive efficacy (Bode and Dong, 2009; Yang et al., 2009). Dietary
intervention with EGCG has great anti-CRC potential; this is due
to its ability to target multiple proteins that are involved in the
development of CRC, as shown in Figures 1–6.
A number of potential mechanisms have been proposed for
the chemopreventive efficacy of EGCG including: enhancement
of antioxidant activity, alteration of hormone and growth factor
signaling, and induction of cell cycle arrest. Due to the polyphe-
nolic structure of EGCG, tea polyphenols are strong antioxidants
and thus prevent the formation of ROS. Similarly, EGCG has
been shown to initiate transcription factors in CRC cells, such
as Nrf2, which further induces phase II enzymes such as UDP-
glucuronosyltransferases (UGTs) (Zhang et al., 2009). Further-
more, EGCG decreases growth and hormone signals specifically
EGF, IGF-1, and VEGF indicating its role in proliferation, insulin,
and metastatic signaling (Khan and Mukhtar, 2008). In addition,
EGCG inhibits additional proliferative and cellular division path-
ways in CRC cells, via down regulation of MAPK/ERK1/2 and p21
pathways, ultimately resulting in cell cycle arrest (Lin et al., 1999;
Larsen and Dashwood, 2010). Moreover, EGCG has the ability to
induce apoptotic death of cancer cells via p53, p21, and PUMA up
regulation (Thakur et al., 2010). EGCG can also modify epigenetic
expression patterns in CRC cells via alteration of DNMT activ-
ity, resulting in gene silencing (Fang et al., 2003). EGCG was also
observed to inhibit β-catenin translocation and VEGF expression,
www.frontiersin.org May 2013 | Volume 3 | Article 119 | 13
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Derry et al. Lifestyle modifications in CRC
which further supports its chemopreventive efficacy (Kondo et al.,
2002).
THE ROLE OF VACCINATION FOR CRC PREVENTION
Chronic inflammatory conditions have been shown to increase
the incidence of CRC (Terzic et al., 2010). The question still
remains: does inflammation precede cancer or does cancer precede
inflammation. During chronic inflammation, the tissue environ-
ment contains a diverse population of leukocytes that secrete
and express factors that effect cell proliferation and genomic
instability (Balkwill et al., 2005; Lin and Karin, 2007). Antigen
presenting cells such as dendritic cells (DCs) have the ability to
acquire antigens and migrate to lymph nodes, which can lead to
T-cell stimulation, specifically CD4+ T helper cells and CD8+
cytotoxic T lymphocytes (CTLs). These cells can be hijacked for
anti-tumor activity; furthermore, vaccines have been designed to
present antigens against cancer cells, causing immune cell infiltra-
tion in the tumor microenvironment, and resulting in decreased
tumor growth. This immune recognition is mediated by toll-like
receptors (TLRs) which bridge the innate and adaptive immunity
(Iwasaki and Medzhitov, 2004). Specific cancer antigens including
carcinoembryonic antigen (CEA), are utilized clinically to monitor
CRC disease progression and is one of the most promising tumor
associated antigens (TAAs) (Thompson et al., 1991). The theory
behind cancer vaccination is that priming of the innate immu-
nity to neoantigens may clear the tissue site and prevent chronic
inflammation, or with tumor specific neoantigens, vaccination
could prevent cancer progression. There have been several clin-
ical trials investigating vaccination for CRC, DC based vaccines in
particular, that have shown to induce a specific immune response
(Mosolits et al., 2005). Furthermore, vaccination has great clinical
potential with treatment resistant patient sub-types; this is due to
its ability to target specific proteins that are involved in the pro-
gression of CRC. Vaccination inhibits multiple processes that are
involved in the development of metastatic CRC including growth
and oncogenic signaling, and inflammatory processes, as shown
in Figures 1,2,4, and 5.
Tumor vaccines have been designed to target oncogenes, specif-
ically c-myc, which is over expressed in 80% of CRC; vaccination
resulted in generation of CD4+ and CD8+ T cells that infiltrated
the tumor site (Williams et al., 2008). Additionally, these have been
designed to target other mediators, such as TGF-β which plays a
role in inflammatory, proliferative, and apoptotic pathways; vac-
cination resulted in inhibition of tumor growth (Roberts, 2002).
Furthermore, CRC vaccines have been designed to target epithelial
specific proteins such as MUC1, which is over expressed in chronic
inflammatory diseases such as, inflammatory bowel disease; result-
ing in an increased innate immune response and decreased chronic
inflammation (Beatty et al., 2007; Furr et al., 2010). Consequently,
the anti-tumor efficacy of the MUC1 vaccine was mediated by
CD4+ T cells, FasL, and TNF-α signaling, resulting in induction
of the innate immunity and apoptosis (Sugiura et al., 2008). Clin-
ically, anti-VEGF (Bevacizumab) vaccines are currently utilized,
however, adverse effects have been observed, and therefore, dif-
ferent vaccination formulations are being designed against VEGF
with anti-metastatic potential and no toxicity, supporting a role
for vaccination in the prevention of CRC (Rad et al., 2007).
LIFESTYLE RECOMMENDATIONS
Consumption of red meat is standard in the normal American
diet; however, due to the numerous associations between red meat
consumption and CRC risk, it is recommended to limit the con-
sumption of red meat to 50 g/day, which is equivalent to 2 oz, about
1/2 the size of your palm. Additionally, consuming other food-
stuffs along with red meat could be beneficial in decreasing the
detrimental effects of red meat consumption. For example, pro-
biotic consumption alters heme metabolism and reduces inflam-
mation. Probiotics, fiber, silibinin, and CUR have the ability to
increase DNA repair enzymes; again, neutralizing the detrimental
effects of high red meat consumption. Furthermore, nutraceuticals
such as GSE, silibinin, and CUR have all been shown to possess
anti-inflammatory effects, indicating that these agents would be
beneficial in inhibiting red meat-induced inflammation.
Alcohol is considered a carcinogen, and therefore, to prevent
CRC, daily intake of alcohol should be kept to 20 g/day or below
to be considered as safe exposure, which is equivalent to approxi-
mately two glasses of wine or beer (Haas et al., 2012). Additionally,
other measures can be taken to limit toxicity. Probiotics not only
can increase DNA repair enzymes, but these organisms also pro-
duce folic acid, which is a chronic nutrition deficient in individuals
that consume alcohol on a regular basis. In addition, folic acid sup-
plementation has been shown to decrease the incidence of DNA
mutations that may result following alcohol exposure. Further-
more, alcohol consumption has been shown to increase prolifera-
tion; in contrast fiber, GSE, silibinin, CUR, and EGCG have been
shown to alter β-catenin signaling resulting in decreased prolif-
eration rates. Downstream targets of β-catenin signaling include
MMP-7, which is involved in CRC metastatic disease progression.
Nutraceuticals such as silibinin and CUR have been shown to
decrease MMPs expression, specifically MMP-2 and MMP-7, indi-
cating the ability of these supplements to decrease the detrimental
effects that result from chronic alcohol exposure.
Tobacco smoke contains nicotine and numerous carcinogenic
compounds that result in colon carcinogenesis, and there are no
safe exposure guidelines for tobacco smoke. Therefore, for prevent-
ing CRC, individuals should not smoke tobacco, and additional
lifestyle modifications should be considered. Specifically, food-
stuffs that target carcinogen detoxification through up regulation
of GSTs and DNA repair proteins would be extremely benefi-
cial; these include probiotics, folic acid, fiber, and phytochemicals
such as, silibinin and CUR. Additionally, tobacco smoke exposure
results in epigenetic modifications of KRAS and BRAF, and con-
sumption of fiber, GSE, or EGCG has the ability to inhibit these
epigenetic changes. Similarly, the epigenetic modifications result-
ing from tobacco exposure can initiate alterations in proliferative
and apoptotic signaling cascades, resulting in uncontrolled prolif-
eration and apoptosis resistance. To counteract this, it would be
beneficial to consume EGCG, which has been shown to inhibit
aberrant β-catenin signaling, inhibit proliferation, and inflamma-
tory signaling. Furthermore, nutraceuticals such as, GSE, silibinin,
fiber, EGCG, and CUR have all been shown to induce apoptotic
cancer cell death. In addition, probiotics, GSE, silibinin, CUR,
and EGCG all produce anti-inflammatory effects, which would
be beneficial in inhibiting the inflammatory mediators that are up
regulated in response to tobacco smoke and contribute to CRC
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disease promotion and progression. Coupled with the fact that
silibinin has also been shown to inhibit VEGF levels, these dietary
factors have enormous potential for CRC prevention as a result of
tobacco exposure.
Obesity has become a major epidemic in the US, and obesity-
related conditions such as cancer are on the rise as well. The most
significant lifestyle intervention that would prevent CRC develop-
ment and be further beneficial to overweight and obese individuals
would be increased physical activity. This change in lifestyle would
result in decreased adipose tissue and thus decrease angiogenic and
inflammatory mediators that are released from the fat tissue. In
addition, physical activity has the ability to prevent chronic inflam-
mation, through inhibition of TNFα and induction of the innate
immune response. Moreover, physical activity also increases the
release of hormones that regulate satiety signals, ultimately restor-
ing the balance between energy intake and expenditure. However,
there are a number of diet alterations that can also modify obesity-
related signals, specifically, GSE, silibinin, probiotics, and EGCG
have all been shown to beneficially modify insulin signaling. Like
physical activity, additional nutraceuticals can alter GST activa-
tion; these include probiotics, fiber, silibinin, and CUR, all of which
result in increased detoxification. Obesity-induced CRC is also
related to uncontrolled proliferation rates, which also could be
modified through fiber, GSE, and EGCG supplementation. Fur-
thermore, consumption of silibinin or CUR could decrease VEGF
levels, which are elevated in obese individuals, further inhibiting
CRC disease progression and metastasis.
Maintaining a regular daily schedule that coincides with the
circadian rhythm is important in preventing cancer development
including CRC. Furthermore, as a proof of principle, these clock
genes are suppressed during CRC promotion and progression. It
would be recommended to work day shifts; however, that may not
be an option for everyone. If night-shift work is necessary, supple-
menting with compounds that decrease inflammation and control
the cell cycle could alleviate the damaging effects of circadian
rhythm disruption. Specifically, probiotics, fiber, GSE, silibinin,
CUR, EGCG, and specific vaccinations all decrease inflammation.
Moreover, fiber, GSE, silibinin, CUR, and EGCG modulate p21
protein, which causes cancer cell cycle arrest as well as inhibition
of proliferation.
Overall, the above lifestyle choices can result in damaging
or beneficial effects, the key is to find a balance. Further-
more, increasing the protective lifestyle factors is associated with
decreased rates and incidence of CRC. The current knowledge
highlights the multiple pathways and molecular targets involved
in lifestyle choices that can result in CRC progression or pre-
vention. This comprehensive review sheds light on the etiol-
ogy and pathogenesis of CRC, and provides additional evi-
dence that lifestyle modifications are important of the prevention
of CRC.
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